Autonomix Medical, Inc. Granted New U.S. Patent to Advance Minimally Invasive, Nerve-Focused Treatments Across High-Need Indications

Rhea-AI Summary

Autonomix Medical (NASDAQ: AMIX) has been granted U.S. Patent No. 12,295,646 for its "Smart Torquer" device, strengthening its intellectual property portfolio in nerve-sensing and modulation technology. The patent covers a device designed to enhance the manipulation of intravascular devices during minimally invasive procedures while enabling data communication.

The company's technology platform features a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with enhanced sensitivity, followed by proprietary RF ablation for targeted nerve treatment. With over 80 issued patents and 40 pending applications, Autonomix is positioning itself in a multi-billion-dollar market opportunity across cardiovascular, renal, and other high-burden diseases.

Positive

• Patent portfolio expanded with over 80 issued patents and 40 pending applications
• Technology addresses multi-billion-dollar market opportunity
• First-in-class technology platform with enhanced neural signal detection capabilities
• Potential applications across multiple high-value medical areas including cardiology, neurosurgery, and pain management

Negative

• None.

Insights

Medical Device Patent Specialist

Autonomix strengthens competitive position with key patent for smart torquer device, enhancing its nerve-targeting platform capabilities.

Autonomix Medical's newly granted U.S. Patent No. 12,295,646 represents a significant enhancement to their intellectual property portfolio in the specialized field of nerve-sensing and modulation technologies. This patent specifically covers a smart torquer device that integrates mechanical control with data communication capabilities, a critical advancement for precise manipulation of intravascular devices.

The technology incorporates several key innovations: an engaging mechanism for secure attachment to intravascular devices, a communication module for data exchange, an electrical connection interface for signal transmission, and a manipulator enabling controlled torque application during vascular navigation. These features directly support Autonomix's catheter-based microchip sensing technology that aims to detect neural signals with greater sensitivity than existing solutions.

The strategic value of this patent extends beyond the immediate technological application. With over 80 issued patents and 40 pending applications, Autonomix is establishing a formidable barrier to competition in a specialized market segment. This comprehensive IP strategy creates a defensible position for their sense-treat-verify approach across multiple high-value therapeutic areas including chronic pain management, hypertension, and cardiology.

This patent reinforces Autonomix's technological differentiation in minimally invasive nerve-targeted treatments, potentially expanding their addressable market into high-growth medical specialties including cardiology, neurosurgery, and interventional radiology - fields where precise nerve modulation could significantly improve treatment outcomes and patient quality of life.

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases

THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,295,646 (the ‘646 patent), titled, “Smart Torquer and Methods for Using the Same.” The newly issued ‘646 patent relates to a smart torquer device designed to enhance the manipulation of elongated intravascular devices during minimally invasive procedures, while integrating electronic components to facilitate both mechanical control and data communication.

“This patent strengthens our intellectual property portfolio and reinforces our commitment to developing differentiated technologies that address large and underserved markets. The smart torquer improves control and signal integration for intravascular procedures, which is essential for expanding our platform into high-growth areas like cardiology, neurosurgery, and interventional radiology. With the addition of this ‘646 patent to our over 80 issued patents, Autonomix is building a defensible position in a multi-billion-dollar opportunity where precision nerve-targeted interventions can reshape clinical outcomes,” commented Brad Hauser, CEO of Autonomix.

In particular, the ‘646 patent relates to, but is not limited to, an engaging mechanism that securely attaches to an intravascular device, a communication module that facilitates data exchange between systems, an electrical connection interface to transmit signals and a manipulator that allows the user to apply torque to the engaged device as it navigates the vascular system.

Autonomix’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary RF ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.

For more information about the Company’s technology, please visit autonomix.com.

About Autonomix Medical, Inc.

Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.

We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.

For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.

Forward Looking Statements

Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer and other indications and the ability of our patents to strengthen our strategic position. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”

Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor and Media Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com

FAQ

What is the new patent granted to Autonomix Medical (NASDAQ: AMIX)?

Autonomix Medical was granted U.S. Patent No. 12,295,646 for its 'Smart Torquer' device, which enhances the manipulation of intravascular devices during minimally invasive procedures while enabling data communication.

How many patents does Autonomix Medical (AMIX) currently hold?

Autonomix Medical holds over 80 issued patents and has 40 pending patent applications in nerve-sensing and modulation technology.

What medical conditions can Autonomix Medical's (AMIX) technology potentially treat?

The technology platform can potentially treat various conditions across cardiovascular, renal, chronic pain management, hypertension, and other high-burden diseases.

How does Autonomix Medical's (AMIX) nerve detection technology work?

The technology uses a catheter-based microchip sensing array antenna to detect and differentiate neural signals, followed by proprietary RF ablation technology to precisely target and treat specific nerves.

What markets is Autonomix Medical (AMIX) targeting with its technology?

Autonomix is targeting multiple high-growth medical areas including cardiology, neurosurgery, interventional radiology, and chronic pain management, representing a multi-billion-dollar market opportunity.